At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 85 enrolled
Drug / intervention
dasatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Studies of Two Different Schedules of Dasatinib (NSC-732517) in Bone Metastasis Predominant Metastatic Breast Cancer
In Brief
A Phase 2 clinical trial evaluating dasatinib for Breast Cancer and Metastatic Cancer. Completed, enrolled 85 participants across 117 sites.
Detailed Summary
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This randomized phase II trial is studying two different schedules of dasatinib to compare how well they work in treating patients with stage IV breast cancer that has spread to the bone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Metastatic Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 2006
Enrollment StartMar 2007
Primary CompletionJan 2013
Study CompletionJan 2014
TodayJul 2026
First PostedDec 13, 2006
Enrollment StartMar 1, 2007
Primary CompletionJan 1, 2013
Study CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 19.6 years ago
Interventions
dasatinibdrug
given orally